Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
The price of Niagen Bioscience Inc (NASDAQ: NAGE) closed at $6.6 in the last session, down -4.07% from day before closing price of $6.88. In other words, the price has decreased by -$4.07 from its previous closing price. On the day, 1.76 million shares were traded. NAGE stock price reached its highest trading level at $7.55 during the session, while it also had its lowest trading level at $6.58.
Ratios:
We take a closer look at NAGE’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 8.19 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 24.98. For the most recent quarter (mrq), Quick Ratio is recorded 3.29 and its Current Ratio is at 4.12. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.03.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Canaccord Genuity on May 27, 2025, initiated with a Buy rating and assigned the stock a target price of $13.
B. Riley Securities Downgraded its Buy to Neutral on August 11, 2022, whereas the target price for the stock was revised from $6 to $2.40.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 07 ’25 when Lopez Carlos Luis bought 273 shares for $7.86 per share. The transaction valued at 2,146 led to the insider holds 2,251 shares of the business.
Jaksch Frank L Jr sold 37,161 shares of NAGE for $229,956 on Dec 13 ’24. The Director now owns 244,179 shares after completing the transaction at $6.19 per share. On Dec 13 ’24, another insider, Frank Jaksch Jr., who serves as the affiliate of the company, bought 37,161 shares for $6.19 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NAGE now has a Market Capitalization of 526720480 and an Enterprise Value of 467505312. As of this moment, Niagen’s Price-to-Earnings (P/E) ratio for their current fiscal year is 27.12, and their Forward P/E ratio for the next fiscal year is 22.52. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.46. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.22 while its Price-to-Book (P/B) ratio in mrq is 7.44. Its current Enterprise Value per Revenue stands at 3.749 whereas that against EBITDA is 23.283.
Stock Price History:
The Beta on a monthly basis for NAGE is 2.31, which has changed by 0.058461547 over the last 52 weeks, in comparison to a change of 0.13355756 over the same period for the S&P500. Over the past 52 weeks, NAGE has reached a high of $14.69, while it has fallen to a 52-week low of $5.16. The 50-Day Moving Average of the stock is -21.56%, while the 200-Day Moving Average is calculated to be -25.03%.
Shares Statistics:
According to the various share statistics, NAGE traded on average about 1.12M shares per day over the past 3-months and 1120330 shares per day over the past 10 days. A total of 79.64M shares are outstanding, with a floating share count of 51.42M. Insiders hold about 35.52% of the company’s shares, while institutions hold 36.75% stake in the company. Shares short for NAGE as of 1760486400 were 4172117 with a Short Ratio of 3.72, compared to 1757894400 on 3939095. Therefore, it implies a Short% of Shares Outstanding of 4172117 and a Short% of Float of 7.91.
Earnings Estimates
A comprehensive evaluation of Niagen Bioscience Inc (NAGE) is underway, with the input of 1.0 analysts contributing to its current rating.The consensus estimate for the next quarter is $0.05, with high estimates of $0.05 and low estimates of $0.05.
Analysts are recommending an EPS of between $0.15 and $0.15 for the fiscal current year, implying an average EPS of $0.15. EPS for the following year is $0.22, with 1.0 analysts recommending between $0.22 and $0.22.
Revenue Estimates
According to 5 analysts,. The current quarter’s revenue is expected to be $32.63M. It ranges from a high estimate of $34.37M to a low estimate of $30.5M. As of. The current estimate, Niagen Bioscience Inc’s year-ago sales were $29.12MFor the next quarter, 5 analysts are estimating revenue of $35.65M. There is a high estimate of $36.2M for the next quarter, whereas the lowest estimate is $35.1M.
A total of 5 analysts have provided revenue estimates for NAGE’s current fiscal year. The highest revenue estimate was $128.57M, while the lowest revenue estimate was $126.05M, resulting in an average revenue estimate of $126.93M. In the same quarter a year ago, actual revenue was $99.6MBased on 4 analysts’ estimates, the company’s revenue will be $152.03M in the next fiscal year. The high estimate is $155M and the low estimate is $148.56M.
